FDA grants Fast Track designation to PDS0101 + Keytruda in recurrent or metastatic HPV16-positive HNC

Ready or not, AI-based decision support tools are entering oncology clinics
Regulators and health systems must adapt

Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.

November 15, 2024

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

LSU Health New Orleans was awarded a five-year, $3.1 million grant from the National Institute of Dental and Craniofacial Research.

November 15, 2024

Vol.50 No.43

Clinical Roundup

Keytruda improves outcomes in soft tissue sarcoma

Addition of the immunotherapy drug pembrolizumab (Keytruda) to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial led by researchers from the University of Pittsburgh, UPMC, Duke University, and Princess Margaret Cancer Centre.

November 15, 2024

Vol.50 No.43

Clinical Roundup

Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

Promising preliminary results from an ongoing investigator-initiated phase I clinical trial evaluating the safety and efficacy of a combined regimen of Keytrua (pembrolizumab) and Lymphir (denileukin diftitox-cxdl or E7777) in patients with recurrent solid tumors were announced.

November 15, 2024

Vol.50 No.43

Drugs & Targets

FDA approves Aucatzyl for adults with r/r B-cell precursor ALL

FDA approved Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

November 15, 2024

Vol.50 No.43

Drugs & Targets

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

FDA has approved MI Cancer Seek for use as a companion diagnostic to identify patients with cancer who may benefit from treatment with targeted therapies.

November 08, 2024

Vol.50 No.42

FDA grants Fast Track designation to PDS0101 + Keytruda in recurrent or metastatic HPV16-positive HNC

YOU MAY BE INTERESTED IN

Ready or not, AI-based decision support tools are entering oncology clinics
Regulators and health systems must adapt

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

Keytruda improves outcomes in soft tissue sarcoma

Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

FDA approves Aucatzyl for adults with r/r B-cell precursor ALL

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

Renew today!

Subscriber content

Never miss an issue!

Login

FDA grants Fast Track designation to PDS0101 + Keytruda in recurrent or metastatic HPV16-positive HNC

YOU MAY BE INTERESTED IN

Ready or not, AI-based decision support tools are entering oncology clinicsRegulators and health systems must adapt

LSU Health New Orleans receives $3.1M grant to study head-and-neck cancer incidence in people living with HIV

Keytruda improves outcomes in soft tissue sarcoma

Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

FDA approves Aucatzyl for adults with r/r B-cell precursor ALL

FDA approves MI Cancer Seek as a CDx test for adults and pediatric patients

Never miss an issue!

Login

Ready or not, AI-based decision support tools are entering oncology clinics
Regulators and health systems must adapt